Virginia Kimball Dalton

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment
    Virginia Kimball Dalton
    Department of Medicine, Children s Hospital, Boston, MA 02115, USA
    J Clin Oncol 21:2953-60. 2003
  2. ncbi Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity
    Deborah P Waber
    Department of Psychiatry, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 22:2701-7. 2004
  3. ncbi Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience
    John M Goldberg
    Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3616-22. 2003

Collaborators

Detail Information

Publications3

  1. ncbi Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment
    Virginia Kimball Dalton
    Department of Medicine, Children s Hospital, Boston, MA 02115, USA
    J Clin Oncol 21:2953-60. 2003
    ....
  2. ncbi Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity
    Deborah P Waber
    Department of Psychiatry, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 22:2701-7. 2004
    ....
  3. ncbi Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience
    John M Goldberg
    Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3616-22. 2003
    ..Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure...